🇺🇸 FDA
Patent

US 11084884

Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema

granted A61KA61K2039/505A61K2039/545

Quick answer

US patent 11084884 (Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema) held by Takeda Pharmaceutical Company Limited expires Mon Aug 05 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Aug 10 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 05 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K2039/505, A61K2039/545, A61P, A61P7/10